STAAR Surgical Stock Surges 21% After Q2 Sales Beat Expectations; Uplifts FY21 Outlook

  • STAAR Surgical Company STAA Q2 sales increased 77% Y/Y to $62.4 million and up 23% on a sequential basis, beating the consensus of $52.56 million.
  • The growth was attributable to global ICL sales growth, up 93% to $59.2 million. 
  • Q2 EPS reached $0.27, up from $0.03 a year ago.
  • The gross margin expanded from 69.4% in Q2 FY20 to 78.9%.
  • Cash and Cash Equivalents at Q2 end was $173.1 million.
  • Outlook: For full-year fiscal 2021, STAAR Surgical expects sales of $227 million - $230 million (consensus $216.2 million), up from the previously provided outlook of $215 million to $217 million. The growth represents 40% Y/Y growth at the midpoint.
  • The Company anticipates robust levels of ICL unit growth in Q3 and Q4 that will exceed 30% Y/Y. 
  • STAAR expects Q3 total net sales of $57 million - $58 million.
  • For the second half and full-year 2021, the Company sees a gross margin of 75% to 77% due to a higher mix of other product sales, STAAR Surgical mentioned in the Q2 earnings call.
  • Price Action: STAA shares are up 21.1% at $155.94 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLong IdeasNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!